At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
Bemcentinibdrug
Likely dose
Bemcentinib 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Nonrandomized Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects
In Brief
A Phase 1 clinical trial evaluating Bemcentinib for Non-Small Cell Lung Cancer and 7 related conditions. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The aims of this Study were to determine: * How much of the Study Drug (bemcentinib) ends up in urine and faeces * How much of the Study Drug and its breakdown products get into the bloodstream * The breakdown products (metabolites) of the Study Drug * The safety of the Study Drug and any side effects that might be associated with it.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Metastatic Pancreatic Cancer, Glioblastoma, Malignant Mesothelioma, COVID-19
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartAug 2022
Primary CompletionSep 2022
First PostedJun 2024
TodayJul 2026
First PostedJun 21, 2024
Enrollment StartAug 2, 2022
Primary CompletionSep 23, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 2.0 years ago
Interventions
Bemcentinibdrug
Each 200 mg dose contains approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib and is administered as a single dose on Day 1 of the study.